Wednesday, 26 August 2026European Markets

NYRSTAR Stock Went Down By Over 13% So Far Today

Loading stream...

(VIANEWS) - Shares of NYRSTAR (BEL 20: NYR.BR) fell by a staggering 13.21% to €0.12 at 13:24 EST on Monday, after five successive sessions in a row of losses. BEL 20 is falling 0.19% to €3,595.89, following the last session's downward trend. This seems, so far, a somewhat down trend trading session today.

NYRSTAR's last close was €0.14, 52.46% under its 52-week high of €0.29.

About NYRSTAR

Nyrstar NV does not have significant operations. Previously, it was engaged in the mining, smelting, and producing of zinc, lead, and other base and precious metals primarily in Europe, Australia, Canada, and the United States. Nyrstar NV was founded in 2007 and is based in Balen, Belgium.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-7.066.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NYRSTAR's stock is considered to be overbought (>=80).

Volatility

NYRSTAR's last week, last month's, and last quarter's current intraday variation average was a negative 2.65%, a positive 0.18%, and a positive 2.68%.

NYRSTAR's highest amplitude of average volatility was 2.65% (last week), 4.16% (last month), and 2.68% (last quarter).

More news about NYRSTAR (NYR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com